Definition of the Best Practices in Clinical Utility of Liquid Biopsy: Clinical Guideline, Technologies, Cost-Effectiveness, Reimbursement, a Unidirectional or Multidirectional Path

• Decipher the tumor shedding mechanism
• Precision medicine-driven cut-off strategy implmentation
• Tired fit-for-purpose liquid biopsy solutions combined with real-world genomic data mining
• 1ctDNA-guided treatment and consideration of cost-effectiveness thresholds

Speakers:

Zheng Feng

Head, Clinical Genomics, Clinical Measurements Sciences

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany